Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP – Research Report), Amneal Pharmaceuticals (AMRX – Research Report) and Hims & Hers Health (HIMS – Research Report).
Crispr Therapeutics AG (CRSP)
In a report issued on November 6, Joon Lee from Truist Financial maintained a Buy rating on Crispr Therapeutics AG, with a price target of $220.00. The company’s shares closed last Wednesday at $54.72.
According to TipRanks.com, Lee is a 4-star analyst with an average return of
Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $82.88, which is a 42.1% upside from current levels. In a report issued on October 27, Barclays also maintained a Buy rating on the stock with a $64.00 price target.
See today’s best-performing stocks on TipRanks >>
Amneal Pharmaceuticals (AMRX)
In a report issued on November 7, Les Sulewski from Truist Financial maintained a Buy rating on Amneal Pharmaceuticals, with a price target of $7.00. The company’s shares closed last Wednesday at $4.06.
According to TipRanks.com, Sulewski is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amneal Pharmaceuticals with a $5.67 average price target, which is a 29.5% upside from current levels. In a report issued on October 23, Goldman Sachs also maintained a Buy rating on the stock with a $5.00 price target.
Hims & Hers Health (HIMS)
In a report issued on November 7, Jailendra Singh from Truist Financial maintained a Hold rating on Hims & Hers Health, with a price target of $10.00. The company’s shares closed last Wednesday at $7.02.
According to TipRanks.com, Singh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Hims & Hers Health has an analyst consensus of Moderate Buy, with a price target consensus of $11.13, representing a 58.3% upside. In a report issued on November 6, Robert W. Baird also maintained a Hold rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRSP:
- Crispr Therapeutics price target lowered to $50 from $55 at RBC Capital
- Crispr Therapeutics price target lowered to $85 from $88 at Needham
- Crispr Therapeutics price target lowered to $56 from $64 at Barclays
- Crispr Therapeutics reports Q3 EPS ($1.41), consensus ($1.95)
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
